Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Income from Continuing Operations (2024 - 2025)

Silence Therapeutics' Income from Continuing Operations history spans 2 years, with the latest figure at 3712000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 120.94% year-over-year to 3712000.0; the TTM value through Dec 2025 reached 82338000.0, down 99.41%, while the annual FY2025 figure was 68184000.0, 53.35% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 3712000.0 at Silence Therapeutics, up from 26244000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 17725000.0 in Q4 2024 and bottomed at 30046000.0 in Q3 2024.